Pfizer CEO Read hasn't given up on tax inversion deals; Novartis' Diovan loss is Ranbaxy Labs' quarterly gain;

@FiercePharma: Tops in FierceAnimalHealth: Lilly divests U.S. animal health assets to Virbac ahead of Novartis deal. Story | Follow @FiercePharma

@EricPFierce: Ranbaxy's New Jersey plant comes through for drugmaker. More | Follow @EricPFierce

@CarlyHFierce: Our newest special report is live! Pharma's top 10 M&A deals of H1 2014. Feature | Follow @CarlyHFierce

> Pfizer ($PFE) CEO Ian Read says he hasn't given up on scoring a tax inversion deal, even with new U.S. rules designed to limit them; on a case-by-case basis, some might offer "meaningful value." Report

> India's generics maker Ranbaxy Laboratories posted its first profit since 2012, thanks to its generic version of the Novartis ($NVS) blood pressure med Diovan. Report

> India-based Lupin reported a 54% leap in quarterly profits, which beat analyst estimates; U.S. sales helped fuel revenue growth. Report

> Sanofi ($SNY) said it had started producing generic drugs in United Arab Emirates via Globalpharma, a UAE company now 66% owned by the French drugmaker. Report

Medical Device News

@FierceMedDev: IPOs: Sientra goes for $75M, while Nevro nerves up for $100M. Report | Follow @FierceMedDev

@VarunSaxena2: Here's my pernicious article. Read it are your own risk. ICYMI yesterday | Follow @VarunSaxena2

@EmilyWFierce: Find out which companies struck gold in the pharma M&A frenzy in FiercePharma's latest special report. Report | Follow @EmilyWFierce

> HealthTrust commits to buying Infraredx coronary imaging tech. Item

> Welch Allyn partners with startup Gentag to create wearable devices. More

> Wright, Tornier merge in $3.3B inversion deal to create extremities and biologics pure play. News

Biotech News

@FierceBiotech: $AMGN, $SNY and Ono band together for open-source R&D. Article | Follow @FierceBiotech

@JohnCFierce: Amgen adds up to 1,100 new job cuts to its global restructuring plan - Wall Street loves it, shares up 5%. News | Follow @JohnCFierce

@DamianFierce: $RNA CEO on $SRPT's setback: "We are all in this together." More from CNBC | Follow @DamianFierce

@EmilyMFierce: Salk's 100th: Anti-Vaccination Would Trouble Polio Hero. More from LiveScience | Follow @EmilyMFierce

> Novartis chief Jimenez predicts 'multi-blockbuster' success for star heart drug. Article

> Advent joins the parade of new biotech funds with $235M war chest. Item

> Receptos' lead drug scores another promising PhII--this time for ulcerative colitis. News

> Bristol-Myers nabs a HER2 cancer drug in $475M option deal with F-star. Report

Biotech Research News

> Government halts research on dangerous airborne pathogens. Item

> Toxin-producing stem cells designed to kill brain cell tumors. Report

> Brain cells reprogrammed from skin cells offer treatment hope for Huntington's. Story

> Case Western, Janssen, Oncodesign scientists ID anti-inflammatory compounds. More

> Protein discovery could help kill stubborn latent HIV. Article

Pharma Manufacturing News

> Australia's CSL gets three Novartis vaccine plants in $275M deal. News

> Ranbaxy's New Jersey plant comes through for drugmaker. Item

> Hikma gets FDA warning letter for plant in Portugal. More

> Fujifilm adding Texas-based vaccine specialist to its fold. Story

> U.S. Attorney subpoenas Novo for info on Denmark plant. Article

And Finally...The FDA's staff reviewers recommended that Daiichi Sankyo's new blood thinner be approved, but with limits. Report

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.